<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="IntRheumatology International0172-81721437-160XSpringer Berlin HeidelbergBerlin/Heidelberg pmcid: 73601254639 doi: 10.1007/s00296-020-04639-9 : Review" exact="Autoimmune" post="and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2"/>
 <result pre="Berlin HeidelbergBerlin/Heidelberg pmcid: 73601254639 doi: 10.1007/s00296-020-04639-9 : Review Autoimmune and" exact="rheumatic" post="musculoskeletal diseases as a consequence of SARS-CoV-2 infection and"/>
 <result pre="HeidelbergBerlin/Heidelberg pmcid: 73601254639 doi: 10.1007/s00296-020-04639-9 : Review Autoimmune and rheumatic" exact="musculoskeletal diseases" post="as a consequence of SARS-CoV-2 infection and its treatment"/>
 <result pre="Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2" exact="infection" post="and its treatment http://orcid.org/0000-0003-3224-1151ShahSanketsanketimmunology@gmail.com1http://orcid.org/0000-0002-2121-0942DandaDebashishdebashish.danda@cmcvellore.ac.in2http://orcid.org/0000-0002-3643-3989KavadichandaChengappadoc.chengappa@gmail.com1http://orcid.org/0000-0002-3153-4166DasSaibalsaibaldas123@gmail.com3http://orcid.org/0000-0001-8091-1952AdarshM. B.adarshmb@gmail.com1http://orcid.org/0000-0003-1518-6031NegiVir Singhvsnegi22@yahoo.co.in1[1], grid.414953.e0000000417678301Department of Clinical"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="and effort across the globe. A few others, such as" exact="atypical" post="manifestations of COVID-19 mimicking rheumatic musculoskeletal diseases (RMDs) are"/>
 <result pre="A few others, such as atypical manifestations of COVID-19 mimicking" exact="rheumatic" post="musculoskeletal diseases (RMDs) are being reported.Â Like in many"/>
 <result pre="few others, such as atypical manifestations of COVID-19 mimicking rheumatic" exact="musculoskeletal diseases" post="(RMDs) are being reported.Â Like in many other viral"/>
 <result pre="musculoskeletal diseases (RMDs) are being reported.Â Like in many other" exact="viral" post="infections, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can"/>
 <result pre="are being reported.Â Like in many other viral infections, severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can potentially lead to"/>
 <result pre="being reported.Â Like in many other viral infections, severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) infection can potentially lead to an"/>
 <result pre="reported.Â Like in many other viral infections, severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) infection can potentially lead to an array"/>
 <result pre="many other viral infections, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)" exact="infection" post="can potentially lead to an array of rheumatological and"/>
 <result pre="infection can potentially lead to an array of rheumatological and" exact="autoimmune" post="manifestations by molecular mimicry (cross-reacting epitope between the virus"/>
 <result pre="migrating to the target tissues and exerting cytotoxicity), epitope spreading," exact="viral" post="persistence (polyclonal activation due to the constant presence of"/>
 <result pre="viral persistence (polyclonal activation due to the constant presence of" exact="viral" post="antigens driving immune-mediated injury) and formation of neutrophil extracellular"/>
 <result pre="tried in the treatment of COVID-19 can result in several" exact="rheumatic" post="musculoskeletal adverse effects. In this review, we have addressed"/>
 <result pre="we have addressed the possible spectrum and mechanisms of various" exact="autoimmune" post="and rheumatic musculoskeletal manifestations that can be precipitated by"/>
 <result pre="addressed the possible spectrum and mechanisms of various autoimmune and" exact="rheumatic" post="musculoskeletal manifestations that can be precipitated by COVID-19 infection,"/>
 <result pre="strategies to contain the infection. Keywords Coronavirus disease-2019 (COVID-19) Rheumatic" exact="musculoskeletal diseases" post="(RMDs) Autoimmunity Rheumatology Introduction The coronavirus disease-2019 (COVID-19) pandemic"/>
 <result pre="the spread of the virus, the overall incidence of fresh" exact="infections" post="is still on the rise. Moreover, with no vaccine"/>
 <result pre="at an uncertain future and a long-term coexistence of severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) with the human host has"/>
 <result pre="an uncertain future and a long-term coexistence of severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) with the human host has been"/>
 <result pre="uncertain future and a long-term coexistence of severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) with the human host has been anticipated."/>
 <result pre="facing COVID-19 and its after effects. We have always considered" exact="rheumatic" post="musculoskeletal diseases (RMDs) as conditions that are precipitated when"/>
 <result pre="COVID-19 and its after effects. We have always considered rheumatic" exact="musculoskeletal diseases" post="(RMDs) as conditions that are precipitated when a genetically"/>
 <result pre="knowledge of the host-environment interaction in RMD until now was" exact="limited" post="to epidemiological studies related to small infectious outbreaks like"/>
 <result pre="until now was limited to epidemiological studies related to small" exact="infectious" post="outbreaks like the Chikungunya epidemic which has given us"/>
 <result pre="is a mammoth event in the history of humankind. The" exact="infection" post="has spread across all large countries affecting people from"/>
 <result pre="large countries affecting people from all age groups. Such an" exact="infection" post="is likely to have long-term consequences, and RMDs could"/>
 <result pre="of post-COVID-19 autoimmunity with an increase in the incidence of" exact="Kawasaki disease" post="[4] and Guillain-BarrÃ© syndrome [5, 6]. In a global"/>
 <result pre="post-COVID-19 autoimmunity with an increase in the incidence of Kawasaki" exact="disease" post="[4] and Guillain-BarrÃ© syndrome [5, 6]. In a global"/>
 <result pre="increase in the incidence of Kawasaki disease [4] and Guillain-BarrÃ©" exact="syndrome" post="[5, 6]. In a global attempt to curb this"/>
 <result pre="are known to cause adverse effects mimicking RMDs and other" exact="autoimmune diseases," post="there is a lack of information for the majority"/>
 <result pre="are also concerns regarding the right approach to treat existing" exact="rheumatic" post="diseases and about the outcome of infection among those"/>
 <result pre="to treat existing rheumatic diseases and about the outcome of" exact="infection" post="among those on immunosuppressive agents. This and many more"/>
 <result pre="[9] resulting from the use of immune checkpoint inhibitors in" exact="cancer" post="treatment. The initial dilemma on the management plan and"/>
 <result pre="Objective and search strategy Our objective was to narrate various" exact="autoimmune" post="and rheumatic manifestations that are associated with COVID-19 and"/>
 <result pre="search strategy Our objective was to narrate various autoimmune and" exact="rheumatic" post="manifestations that are associated with COVID-19 and the drugs"/>
 <result pre="and myalgia without dyspnea. The severe presentation includes patients with" exact="respiratory" post="distress as indicated by a respiratory rate ofâ€‰â‰¥â€‰30/min, SpO2"/>
 <result pre="presentation includes patients with respiratory distress as indicated by a" exact="respiratory" post="rate ofâ€‰â‰¥â€‰30/min, SpO2 (blood oxygen saturation) ofâ€‰â‰¤â€‰93%, PaO2 (partial"/>
 <result pre="of oxygen)/FiO2 (fraction of inspired oxygen) ratio ofâ€‰ 13]. Besides" exact="respiratory" post="symptoms, multiple cohorts have reported anosmia and dysgeusia, ranging"/>
 <result pre="the patients [14, 15]. Gastrointestinal manifestations, including nausea, vomiting, and" exact="diarrhea" post="have been reported in 11â€&quot;24% of the cases and"/>
 <result pre="increased eye discharge [18]. The other musculoskeletal, dermatological, neurological, and" exact="cardiovascular" post="manifestations have been discussed in detail further in this"/>
 <result pre="detail further in this review. The risk factors for severe" exact="disease" post="and mortality include old age, immunocompromised status, and comorbidities,"/>
 <result pre="include old age, immunocompromised status, and comorbidities, such as hypertension," exact="diabetes mellitus," post="cardiovascular disease, chronic respiratory disorders, chronic kidney disease, liver"/>
 <result pre="age, immunocompromised status, and comorbidities, such as hypertension, diabetes mellitus," exact="cardiovascular disease," post="chronic respiratory disorders, chronic kidney disease, liver diseases, cancer,"/>
 <result pre="status, and comorbidities, such as hypertension, diabetes mellitus, cardiovascular disease," exact="chronic" post="respiratory disorders, chronic kidney disease, liver diseases, cancer, and"/>
 <result pre="and comorbidities, such as hypertension, diabetes mellitus, cardiovascular disease, chronic" exact="respiratory" post="disorders, chronic kidney disease, liver diseases, cancer, and severe"/>
 <result pre="such as hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disorders," exact="chronic" post="kidney disease, liver diseases, cancer, and severe obesity [19]."/>
 <result pre="as hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disorders, chronic" exact="kidney disease," post="liver diseases, cancer, and severe obesity [19]. Initial data"/>
 <result pre="respiratory disorders, chronic kidney disease, liver diseases, cancer, and severe" exact="obesity" post="[19]. Initial data from the COVID-19 Global Rheumatology Alliance"/>
 <result pre="similar to those in the general population [20]. Spectrum of" exact="rheumatic" post="musculoskeletal manifestations of SARS-CoV-2 infection and antiviral drugs With"/>
 <result pre="general population [20]. Spectrum of rheumatic musculoskeletal manifestations of SARS-CoV-2" exact="infection" post="and antiviral drugs With scientific literature pouring in from"/>
 <result pre="world on the clinical presentations and complications of SARS-CoV-2 infections," exact="atypical" post="clinical and laboratory manifestations mimicking RMDs have been reported"/>
 <result pre="kinase (CK) level [21, 22]. Some of these manifestations preceded" exact="respiratory" post="symptoms of COVID-19. For instance, a patient who presented"/>
 <result pre="For instance, a patient who presented with proximal weakness with" exact="muscle" post="edema on magnetic resonance imaging (MRI), turned negative for"/>
 <result pre="The spectrum of dermatological manifestations mimicking RMDs includes COVID toes/pseudo-chilblain," exact="transient" post="urticarial or maculopapular rash, livedoid/necrotic lesions, punctiform or diffuse"/>
 <result pre="toes/pseudo-chilblain, transient urticarial or maculopapular rash, livedoid/necrotic lesions, punctiform or" exact="diffuse" post="purpura, and erythema elevatum diutinum-like rash [23]. COVID toes/pseudo-chilblain"/>
 <result pre="no association with the duration of infection. Cases of young" exact="stroke" post="involving large vessels, commonly evaluated in rheumatology clinics, have"/>
 <result pre="reported with COVID-19 [24]. A couple of cases of Guillain-BarrÃ©" exact="syndrome" post="(GBS) has been described as a consequence of post-viral"/>
 <result pre="syndrome (GBS) has been described as a consequence of post-viral" exact="autoimmune" post="phenomenon. Out of the two reported cases, one succumbed"/>
 <result pre="phenomenon. Out of the two reported cases, one succumbed to" exact="respiratory" post="complications, and the other recovered with intravenous immunoglobulin (IVIg)/plasmapheresis"/>
 <result pre="patients without any prior cardiac morbidity has been reported with" exact="early onset" post="of cardiac symptoms. They present with intact coronaries in"/>
 <result pre="and MRI showing the classical features of myocarditis. Improvement of" exact="myocarditis" post="was noticed following treatment with hydroxychloroquine, lopinavir/ritonavir, and intravenous"/>
 <result pre="intravenous methylprednisolone [25, 26]. An increase in the incidence of" exact="Kawasaki disease" post="has been reported from Italy as a post-SARS-CoV-2 phenomenon."/>
 <result pre="methylprednisolone [25, 26]. An increase in the incidence of Kawasaki" exact="disease" post="has been reported from Italy as a post-SARS-CoV-2 phenomenon."/>
 <result pre="Italy as a post-SARS-CoV-2 phenomenon. As compared to the classical" exact="Kawasaki disease," post="these children were older (mean age, 7.5Â years) and"/>
 <result pre="to have more cardiac involvement, shock syndrome, and macrophage activation" exact="syndrome" post="(MAS) [4]. Cytokine storm or secondary hemophagocytic lymphohistiocytosis (sHLH),"/>
 <result pre="syndrome, and macrophage activation syndrome (MAS) [4]. Cytokine storm or" exact="secondary" post="hemophagocytic lymphohistiocytosis (sHLH), yet another entity encountered in rheumatology"/>
 <result pre="and macrophage activation syndrome (MAS) [4]. Cytokine storm or secondary" exact="hemophagocytic lymphohistiocytosis" post="(sHLH), yet another entity encountered in rheumatology practice, is"/>
 <result pre="The clinical manifestations start 8â€&quot;9Â days after the onset of" exact="respiratory" post="symptoms and range from unremitting fever, cytopenia, to hyperferritinemia"/>
 <result pre="unremitting fever, cytopenia, to hyperferritinemia ultimately resulting in multiorgan failure." exact="Hyperferritinemia" post="and elevated serum interleukin (IL)-6 are often associated with"/>
 <result pre="cytopenia, to hyperferritinemia ultimately resulting in multiorgan failure. Hyperferritinemia and" exact="elevated serum" post="interleukin (IL)-6 are often associated with mortality in these"/>
 <result pre="laboratory reports of positive antinuclear antibodies (ANA) [28], antiphospholipid antibodies," exact="lupus" post="anti-coagulant assay [29, 30] and increased level of D-dimer"/>
 <result pre="mimicking or precipitating RMDs points towards a possibility of persisting" exact="intermediate" post="to long-term immune dysregulation. Table 1 Rheumatic musculoskeletal manifestations"/>
 <result pre="immune dysregulation. Table 1 Rheumatic musculoskeletal manifestations associated with SARS-CoV-2" exact="infection" post="Reported with SARS-CoV-2 Clinical characteristics Refs. Musculoskeletal manifestations Â"/>
 <result pre="manifestations Â Arthralgia-Myalgia In 14.4â€&quot;44% of the cases Early and" exact="transient" post="features Resolves in 10â€&quot;15Â days [21] Â Acute Myositis"/>
 <result pre="Early and transient features Resolves in 10â€&quot;15Â days [21] Â" exact="Acute" post="Myositis Case report Symptom of myalgia and proximal muscle"/>
 <result pre="Â Acute Myositis Case report Symptom of myalgia and proximal" exact="muscle" post="weakness preceded respiratory symptom of COVID-19 Elevate Creatine kinase"/>
 <result pre="Case report Symptom of myalgia and proximal muscle weakness preceded" exact="respiratory" post="symptom of COVID-19 Elevate Creatine kinase (CK) level (25,384Â"/>
 <result pre="COVID-19 Elevate Creatine kinase (CK) level (25,384Â IU/L) MRI showed" exact="muscle" post="edema Negative MSA and MAAs [22] Dermatological manifestations Â"/>
 <result pre="Inâ€‰~â€‰19â€&quot;59% of the pediatric and young adults Asymmetrical multiple redâ€&quot;purple" exact="pustular" post="or vesicular lesions at distal extremities Relatively late feature"/>
 <result pre="late feature [23] Â Skin rash Inâ€‰~â€‰19% of the cases" exact="Transient" post="(6â€&quot;9Â days) urticarial or maculopapular rash Associated with severe"/>
 <result pre="Transient (6â€&quot;9Â days) urticarial or maculopapular rash Associated with severe" exact="disease" post="Â Purpura Rare Punctiform or diffuse Â Livedoid/necrotic lesions"/>
 <result pre="days) urticarial or maculopapular rash Associated with severe disease Â" exact="Purpura" post="Rare Punctiform or diffuse Â Livedoid/necrotic lesions In 6%"/>
 <result pre="rash Associated with severe disease Â Purpura Rare Punctiform or" exact="diffuse" post="Â Livedoid/necrotic lesions In 6% of the elderly with"/>
 <result pre="Â Livedoid/necrotic lesions In 6% of the elderly with severe" exact="disease" post="Acral and truncal distribution with ischemic features in severe"/>
 <result pre="features in severe cases Â Erythema elevatum diutinum-like rash Rare" exact="Multiple" post="redâ€&quot;purple papulo-nodular lesion over the dorsum of hands Neurological"/>
 <result pre="over the dorsum of hands Neurological manifestations Â Large vessel" exact="stroke" post="in young patients Case reports National Institute of Health"/>
 <result pre="reports National Institute of Health Stroke Score range: 13â€&quot;23 Probably" exact="secondary" post="to endothelitis and coagulopathy secondary to COVID-19 [24] Cardiovascular"/>
 <result pre="Health Stroke Score range: 13â€&quot;23 Probably secondary to endothelitis and" exact="coagulopathy" post="secondary to COVID-19 [24] Cardiovascular manifestations Â Myocarditis in"/>
 <result pre="Stroke Score range: 13â€&quot;23 Probably secondary to endothelitis and coagulopathy" exact="secondary" post="to COVID-19 [24] Cardiovascular manifestations Â Myocarditis in absence"/>
 <result pre="coagulopathy secondary to COVID-19 [24] Cardiovascular manifestations Â Myocarditis in" exact="absence of" post="previous comorbidities Case reports Likely to occur within 7Â"/>
 <result pre="reports Likely to occur within 7Â days of symptoms Circumferential" exact="pericardial effusion," post="global hypokinesia, low ejection fraction and normal cardiac valves"/>
 <result pre="hypokinesia, low ejection fraction and normal cardiac valves on echocardiography" exact="Normal" post="coronary angiography Cardiac MRI: myocardial edema and pattern of"/>
 <result pre="fraction and normal cardiac valves on echocardiography Normal coronary angiography" exact="Cardiac" post="MRI: myocardial edema and pattern of late gadolinium-enhancement fulfilling"/>
 <result pre="and pattern of late gadolinium-enhancement fulfilling Lake Louis criteria of" exact="acute" post="myocarditis Improved with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous"/>
 <result pre="pattern of late gadolinium-enhancement fulfilling Lake Louis criteria of acute" exact="myocarditis" post="Improved with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone"/>
 <result pre="with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone [25, 26]" exact="Multisystem" post="autoinflammatory syndrome Â Cytokine storm/Secondary Hemophagocytic lymphohistiocytosis (sHLH) Represents"/>
 <result pre="care, hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone [25, 26] Multisystem autoinflammatory" exact="syndrome" post="Â Cytokine storm/Secondary Hemophagocytic lymphohistiocytosis (sHLH) Represents critical patients"/>
 <result pre="intravenous methylprednisolone [25, 26] Multisystem autoinflammatory syndrome Â Cytokine storm/Secondary" exact="Hemophagocytic lymphohistiocytosis" post="(sHLH) Represents critical patients with SARS-CoV-2 infection After 8â€&quot;9Â"/>
 <result pre="Cytokine storm/Secondary Hemophagocytic lymphohistiocytosis (sHLH) Represents critical patients with SARS-CoV-2" exact="infection" post="After 8â€&quot;9Â days of the symptom onset Unremitting fever,"/>
 <result pre="days of the symptom onset Unremitting fever, cytopenia, and hyperferritinemia" exact="Acute respiratory distress syndrome" post="and multiple organ failure Interplay of Interferons, interleukins, chemokines,"/>
 <result pre="of the symptom onset Unremitting fever, cytopenia, and hyperferritinemia Acute" exact="respiratory" post="distress syndrome and multiple organ failure Interplay of Interferons,"/>
 <result pre="symptom onset Unremitting fever, cytopenia, and hyperferritinemia Acute respiratory distress" exact="syndrome" post="and multiple organ failure Interplay of Interferons, interleukins, chemokines,"/>
 <result pre="failure Interplay of Interferons, interleukins, chemokines, colony-stimulating factors, and TNF-alpha" exact="Hyperferritinemia" post="and elevated serum IL-6, associated with mortality H-score ofâ€‰&amp;gt;â€‰169,"/>
 <result pre="of Interferons, interleukins, chemokines, colony-stimulating factors, and TNF-alpha Hyperferritinemia and" exact="elevated serum" post="IL-6, associated with mortality H-score ofâ€‰&amp;gt;â€‰169, 93% sensitivity and"/>
 <result pre="with IL-1 and IL-6 inhibitor [27] Post-viral autoimmunity Â Guillain-BarrÃ©" exact="syndrome" post="(GBS) Case reports The interval from COVID symptoms to"/>
 <result pre="interval from COVID symptoms to GBS symptoms was 5â€&quot;10Â days" exact="Axonal" post="or demyelinating variant Negative PCR for SARS-CoV-2 from CSF"/>
 <result pre="COVID symptoms to GBS symptoms was 5â€&quot;10Â days Axonal or" exact="demyelinating" post="variant Negative PCR for SARS-CoV-2 from CSF One of"/>
 <result pre="for SARS-CoV-2 from CSF One of the patients succumbed to" exact="respiratory" post="complications, and the other recovered with IVIg/plasmapheresis [5, 6]"/>
 <result pre="and the other recovered with IVIg/plasmapheresis [5, 6] Â Kawasaki-like" exact="disease" post="30-fold increased incidence as compared to the pre-COVID time"/>
 <result pre="(7.5Â years) More cardiac involvement, shock syndrome, and macrophage activation" exact="syndrome" post="as compared to pre-COVID-19 Kawasaki disease [4] Laboratory findings"/>
 <result pre="shock syndrome, and macrophage activation syndrome as compared to pre-COVID-19" exact="Kawasaki disease" post="[4] Laboratory findings Â Positive Antinuclear antibodies (ANA) Reported"/>
 <result pre="syndrome, and macrophage activation syndrome as compared to pre-COVID-19 Kawasaki" exact="disease" post="[4] Laboratory findings Â Positive Antinuclear antibodies (ANA) Reported"/>
 <result pre="heparin in patients with antiphospholipid test positivity [29, 30] Â" exact="Increased" post="d-Dimer without DIC &amp;gt;â€‰0.5Â mg/L in 46% of the"/>
 <result pre="2Â·6â€&quot;128Â·6; pâ€‰=â€‰0Â·0033) [31] COVID-19 coronavirus disease-2019, CSF cerebrospinal fluid, DIC" exact="disseminated intravascular coagulation," post="IL interleukin, LAC lupus anti-coagulant, MAA myositis-associated autoantibodies, MSA"/>
 <result pre="CSF cerebrospinal fluid, DIC disseminated intravascular coagulation, IL interleukin, LAC" exact="lupus" post="anti-coagulant, MAA myositis-associated autoantibodies, MSA myositis-specific autoantibodies, RA rheumatoid"/>
 <result pre="LAC lupus anti-coagulant, MAA myositis-associated autoantibodies, MSA myositis-specific autoantibodies, RA" exact="rheumatoid arthritis," post="PCR polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome"/>
 <result pre="autoantibodies, RA rheumatoid arthritis, PCR polymerase chain reaction, SARS-CoV-2 severe" exact="acute" post="respiratory syndrome coronavirus-2 Based on evidence from in-vitro studies"/>
 <result pre="RA rheumatoid arthritis, PCR polymerase chain reaction, SARS-CoV-2 severe acute" exact="respiratory" post="syndrome coronavirus-2 Based on evidence from in-vitro studies and"/>
 <result pre="rheumatoid arthritis, PCR polymerase chain reaction, SARS-CoV-2 severe acute respiratory" exact="syndrome" post="coronavirus-2 Based on evidence from in-vitro studies and experience"/>
 <result pre="Based on evidence from in-vitro studies and experience from other" exact="viral" post="infections, several antiviral therapies are currently in trial/practice in"/>
 <result pre="different parts of the world [32]. There are reports of" exact="rheumatic" post="musculoskeletal adverse reactions following the use of these drugs."/>
 <result pre="adverse events. Of these, some adverse events deserve special mention." exact="Myopathy" post="and neuromyopathy can rarely occur following long-term treatment with"/>
 <result pre="treatment with chloroquine and hydroxychloroquine [33]. Favipiravir can lead to" exact="hyperuricemia" post="[34]. Lopinavir-ritonavir-related rheumatic adverse events include arthralgia, back pain,"/>
 <result pre="and hydroxychloroquine [33]. Favipiravir can lead to hyperuricemia [34]. Lopinavir-ritonavir-related" exact="rheumatic" post="adverse events include arthralgia, back pain, osteonecrosis, and vasculitis"/>
 <result pre="Lopinavir-ritonavir-related rheumatic adverse events include arthralgia, back pain, osteonecrosis, and" exact="vasculitis" post="[35]. Ribavirin can cause arthralgia, back pain, myositis, and"/>
 <result pre="Ribavirin can cause arthralgia, back pain, myositis, and exacerbation of" exact="sarcoidosis" post="[36]. Musculoskeletal pain and myalgia have been reported in"/>
 <result pre="cases, interferon therapy can lead to drug-induced RMDS, such as" exact="rheumatoid arthritis," post="lupus, Sjogren syndrome, myositis, sarcoidosis, and vasculitis [37]. With"/>
 <result pre="can lead to drug-induced RMDS, such as rheumatoid arthritis, lupus," exact="Sjogren syndrome," post="myositis, sarcoidosis, and vasculitis [37]. With the increased use"/>
 <result pre="such as rheumatoid arthritis, lupus, Sjogren syndrome, myositis, sarcoidosis, and" exact="vasculitis" post="[37]. With the increased use of these drugs, there"/>
 <result pre="noted that some of the frontrunner drugs like remdesivir have" exact="limited" post="clinical data making it even more important to be"/>
 <result pre="important to be vigilant. Table 2 Anti-SARS-CoV-2 drugs and its" exact="rheumatic" post="musculoskeletal adverse effects Drugs Antiviral mechanisms Rheumatic musculoskeletal adverse"/>
 <result pre="Inhibit pH-dependent internalization and fusion of the virus with lysosomes" exact="Myopathy" post="and neuromyopathy [33] Favipiravir Inhibit viralÂ RNA-dependent RNA polymerase"/>
 <result pre="inosine monophosphate dehydrogenase Arthralgia (&amp;gt;â€‰10%), musculoskeletal pain (&amp;gt;â€‰10%), backache (1â€&quot;10%)," exact="gout" post="( Exacerbation of sarcoidosis (higher incidence in combination with"/>
 <result pre="(&amp;gt;â€‰10%), musculoskeletal pain (&amp;gt;â€‰10%), backache (1â€&quot;10%), gout ( Exacerbation of" exact="sarcoidosis" post="(higher incidence in combination with interferon Î±) [36] Camostat"/>
 <result pre="(16â€&quot;75%), musculoskeletal pain (1â€&quot;21%), arthralgia (3â€&quot;19%), backache (1â€&quot;19%), amyotrophy (" exact="Arthritis" post="( Other autoimmune disease ( Interferon Î²1a and Î²1b:"/>
 <result pre="(1â€&quot;21%), arthralgia (3â€&quot;19%), backache (1â€&quot;19%), amyotrophy ( Arthritis ( Other" exact="autoimmune disease" post="( Interferon Î²1a and Î²1b: Myalgia (25â€&quot;29%), Backache (23â€&quot;25%),"/>
 <result pre="arthralgia (3â€&quot;19%), backache (1â€&quot;19%), amyotrophy ( Arthritis ( Other autoimmune" exact="disease" post="( Interferon Î²1a and Î²1b: Myalgia (25â€&quot;29%), Backache (23â€&quot;25%),"/>
 <result pre="disease ( Interferon Î²1a and Î²1b: Myalgia (25â€&quot;29%), Backache (23â€&quot;25%)," exact="Autoimmune" post="hepatitis, Immune thrombocytopenia, SLE, osteonecrosis, Sjogren syndrome [37] Convalescent"/>
 <result pre="Interferon Î²1a and Î²1b: Myalgia (25â€&quot;29%), Backache (23â€&quot;25%), Autoimmune hepatitis," exact="Immune thrombocytopenia," post="SLE, osteonecrosis, Sjogren syndrome [37] Convalescent plasma Chance of"/>
 <result pre="Myalgia (25â€&quot;29%), Backache (23â€&quot;25%), Autoimmune hepatitis, Immune thrombocytopenia, SLE, osteonecrosis," exact="Sjogren syndrome" post="[37] Convalescent plasma Chance of transfusion-related adverse events: urticaria,"/>
 <result pre="(25â€&quot;29%), Backache (23â€&quot;25%), Autoimmune hepatitis, Immune thrombocytopenia, SLE, osteonecrosis, Sjogren" exact="syndrome" post="[37] Convalescent plasma Chance of transfusion-related adverse events: urticaria,"/>
 <result pre="Convalescent plasma Chance of transfusion-related adverse events: urticaria, anaphylaxis, transfusion-related" exact="acute" post="lung injury Latent risk of hyperimmune attacks: Possibly via"/>
 <result pre="blunting of endogenous immunity to the virus RNA ribonucleic acid," exact="SJS-TEN" post="Steven Johnson syndrome-toxic epidermal necrolysis, SLE systemic lupus erythematosus"/>
 <result pre="RNA ribonucleic acid, SJS-TEN Steven Johnson syndrome-toxic epidermal necrolysis, SLE" exact="systemic" post="lupus erythematosus Coagulopathy as a consequence of inflammation COVID-19"/>
 <result pre="ribonucleic acid, SJS-TEN Steven Johnson syndrome-toxic epidermal necrolysis, SLE systemic" exact="lupus erythematosus" post="Coagulopathy as a consequence of inflammation COVID-19 cases One"/>
 <result pre="leading to mortality in COVID-19 patients is the presence of" exact="coagulopathy" post="[38]. The autopsy findings of COVID-19 death from a"/>
 <result pre="from a majority of the cases show the presence of" exact="coagulopathy" post="either in the form of deep venous thrombosis, pulmonary"/>
 <result pre="show the presence of coagulopathy either in the form of" exact="deep venous thrombosis," post="pulmonary embolism, or multiple pulmonary thrombi coexisting with acute"/>
 <result pre="of coagulopathy either in the form of deep venous thrombosis," exact="pulmonary embolism," post="or multiple pulmonary thrombi coexisting with acute respiratory distress"/>
 <result pre="the form of deep venous thrombosis, pulmonary embolism, or multiple" exact="pulmonary" post="thrombi coexisting with acute respiratory distress syndrome (ARDS) changes"/>
 <result pre="venous thrombosis, pulmonary embolism, or multiple pulmonary thrombi coexisting with" exact="acute" post="respiratory distress syndrome (ARDS) changes in the lungs [39]."/>
 <result pre="thrombosis, pulmonary embolism, or multiple pulmonary thrombi coexisting with acute" exact="respiratory" post="distress syndrome (ARDS) changes in the lungs [39]. The"/>
 <result pre="embolism, or multiple pulmonary thrombi coexisting with acute respiratory distress" exact="syndrome" post="(ARDS) changes in the lungs [39]. The laboratory markers"/>
 <result pre="changes in the lungs [39]. The laboratory markers of COVID-19" exact="coagulopathy" post="include increased D-dimer level, borderline thrombocytopenia, and prolonged prothrombin"/>
 <result pre="and prolonged prothrombin time [40]. Though the exact mechanism underlying" exact="coagulopathy" post="is unclear, a possibility of local lung-TMA as a"/>
 <result pre="[42]. The association of netosis has also been proposed with" exact="coagulopathy" post="in COVID-19 patients requiring further therapeutic exploration [43]. Moreover,"/>
 <result pre="patients requiring further therapeutic exploration [43]. Moreover, the presence of" exact="lupus" post="anti-coagulant and antiphospholipid antibodies may point towards the autoimmune"/>
 <result pre="of lupus anti-coagulant and antiphospholipid antibodies may point towards the" exact="autoimmune" post="contribution rather than just an epiphenomenon. Thus, linking inflammation"/>
 <result pre="contribution rather than just an epiphenomenon. Thus, linking inflammation to" exact="coagulopathy" post="which is not a common occurrence in other viral"/>
 <result pre="to coagulopathy which is not a common occurrence in other" exact="viral" post="infections suggests the role of immune activation at the"/>
 <result pre="coagulopathy which is not a common occurrence in other viral" exact="infections" post="suggests the role of immune activation at the vessel"/>
 <result pre="in addition to anticoagulants in severe COVID-19 cases [44]. SARS-CoV-2" exact="infection" post="and autoimmunity The interplay of various genetic, hormonal, immunological,"/>
 <result pre="immunological, and environmental factors constitutes the mosaic of autoimmunity [45]." exact="Viral" post="infections play a substantial role in the development of"/>
 <result pre="and environmental factors constitutes the mosaic of autoimmunity [45]. Viral" exact="infections" post="play a substantial role in the development of several"/>
 <result pre="infections play a substantial role in the development of several" exact="autoimmune diseases" post="in individuals with underlying immune dysregulation [46]. Follow up"/>
 <result pre="underlying immune dysregulation [46]. Follow up data from survivors of" exact="viral" post="outbreaks like influenza, Zika, Ebola, and Chikungunya have shown"/>
 <result pre="like influenza, Zika, Ebola, and Chikungunya have shown development of" exact="autoimmune" post="phenomenon within weeks to months after recovery. While GBS,"/>
 <result pre="weeks to months after recovery. While GBS, fulminant type1 diabetes," exact="IgA vasculitis," post="APS have been observed after a previous outbreak of"/>
 <result pre="previous outbreak of influenza [47], transverse myelitis, arthralgia, myalgia, and" exact="arthritis" post="were reported following Zika [48], Chikungunya [49] and Ebola"/>
 <result pre="arthritis were reported following Zika [48], Chikungunya [49] and Ebola" exact="infections" post="[50]. Besides overt clinical manifestations, long-term persistence of autoreactive"/>
 <result pre="with Ebolavirus) have also been demonstrated with some of these" exact="infections" post="[47, 49]. The mechanisms by which viruses disrupt self-tolerance"/>
 <result pre="the background of autoimmunity mosaic [51]. Table 3 enlists known" exact="viral" post="infections and associated autoimmune diseases with the possible mechanisms"/>
 <result pre="background of autoimmunity mosaic [51]. Table 3 enlists known viral" exact="infections" post="and associated autoimmune diseases with the possible mechanisms as"/>
 <result pre="mosaic [51]. Table 3 enlists known viral infections and associated" exact="autoimmune diseases" post="with the possible mechanisms as elaborately described by Smatti"/>
 <result pre="describe some of the possible mechanism of autoimmunity following SARS-CoV-2" exact="infection" post="as follows: Table 3 Mechanisms of autoimmune manifestation following"/>
 <result pre="autoimmunity following SARS-CoV-2 infection as follows: Table 3 Mechanisms of" exact="autoimmune" post="manifestation following different viral infections Molecular mechanisms Viruses Autoimmune"/>
 <result pre="as follows: Table 3 Mechanisms of autoimmune manifestation following different" exact="viral" post="infections Molecular mechanisms Viruses Autoimmune diseases Molecular mimicry Coxsackievirus"/>
 <result pre="follows: Table 3 Mechanisms of autoimmune manifestation following different viral" exact="infections" post="Molecular mechanisms Viruses Autoimmune diseases Molecular mimicry Coxsackievirus Type"/>
 <result pre="of autoimmune manifestation following different viral infections Molecular mechanisms Viruses" exact="Autoimmune" post="diseases Molecular mimicry Coxsackievirus Type 1 diabetes mellitus Cytomegalovirus"/>
 <result pre="viral infections Molecular mechanisms Viruses Autoimmune diseases Molecular mimicry Coxsackievirus" exact="Type 1" post="diabetes mellitus Cytomegalovirus Multiple sclerosis, type 1 diabetes mellitus,"/>
 <result pre="Molecular mechanisms Viruses Autoimmune diseases Molecular mimicry Coxsackievirus Type 1" exact="diabetes mellitus" post="Cytomegalovirus Multiple sclerosis, type 1 diabetes mellitus, anti-Î²2 glycoprotein-1"/>
 <result pre="Autoimmune diseases Molecular mimicry Coxsackievirus Type 1 diabetes mellitus Cytomegalovirus" exact="Multiple" post="sclerosis, type 1 diabetes mellitus, anti-Î²2 glycoprotein-1 antibody Enterovirus"/>
 <result pre="Molecular mimicry Coxsackievirus Type 1 diabetes mellitus Cytomegalovirus Multiple sclerosis," exact="type 1 diabetes mellitus," post="anti-Î²2 glycoprotein-1 antibody Enterovirus Type 1 diabetes mellitus Epstein-Barr"/>
 <result pre="Coxsackievirus Type 1 diabetes mellitus Cytomegalovirus Multiple sclerosis, type 1" exact="diabetes mellitus," post="anti-Î²2 glycoprotein-1 antibody Enterovirus Type 1 diabetes mellitus Epstein-Barr"/>
 <result pre="Multiple sclerosis, type 1 diabetes mellitus, anti-Î²2 glycoprotein-1 antibody Enterovirus" exact="Type 1" post="diabetes mellitus Epstein-Barr virus Graveâ€™s disease, Hashimotoâ€™s disease, multiple"/>
 <result pre="type 1 diabetes mellitus, anti-Î²2 glycoprotein-1 antibody Enterovirus Type 1" exact="diabetes mellitus" post="Epstein-Barr virus Graveâ€™s disease, Hashimotoâ€™s disease, multiple sclerosis Hepatitis"/>
 <result pre="Type 1 diabetes mellitus Epstein-Barr virus Graveâ€™s disease, Hashimotoâ€™s disease," exact="multiple sclerosis" post="Hepatitis C virus Immune thrombocytopenia, autoimmune hepatitis, polyarthritis Herpes"/>
 <result pre="diabetes mellitus Epstein-Barr virus Graveâ€™s disease, Hashimotoâ€™s disease, multiple sclerosis" exact="Hepatitis" post="C virus Immune thrombocytopenia, autoimmune hepatitis, polyarthritis Herpes simplex"/>
 <result pre="virus Graveâ€™s disease, Hashimotoâ€™s disease, multiple sclerosis Hepatitis C virus" exact="Immune thrombocytopenia," post="autoimmune hepatitis, polyarthritis Herpes simplex virus Human herpes encephalitis"/>
 <result pre="disease, Hashimotoâ€™s disease, multiple sclerosis Hepatitis C virus Immune thrombocytopenia," exact="autoimmune hepatitis," post="polyarthritis Herpes simplex virus Human herpes encephalitis Human T-lymphotropic"/>
 <result pre="virus Immune thrombocytopenia, autoimmune hepatitis, polyarthritis Herpes simplex virus Human" exact="herpes" post="encephalitis Human T-lymphotropic virus-1 Myelopathy/tropical spastic paraparesis Influenza Acute"/>
 <result pre="Immune thrombocytopenia, autoimmune hepatitis, polyarthritis Herpes simplex virus Human herpes" exact="encephalitis" post="Human T-lymphotropic virus-1 Myelopathy/tropical spastic paraparesis Influenza Acute disseminated"/>
 <result pre="Herpes simplex virus Human herpes encephalitis Human T-lymphotropic virus-1 Myelopathy/tropical" exact="spastic paraparesis" post="Influenza Acute disseminated encephalomyelitis Measles virus Multiple sclerosis Theilerâ€™s"/>
 <result pre="Human herpes encephalitis Human T-lymphotropic virus-1 Myelopathy/tropical spastic paraparesis Influenza" exact="Acute" post="disseminated encephalomyelitis Measles virus Multiple sclerosis Theilerâ€™s virus Multiple"/>
 <result pre="encephalitis Human T-lymphotropic virus-1 Myelopathy/tropical spastic paraparesis Influenza Acute disseminated" exact="encephalomyelitis" post="Measles virus Multiple sclerosis Theilerâ€™s virus Multiple sclerosis Varicella-Zoster"/>
 <result pre="virus-1 Myelopathy/tropical spastic paraparesis Influenza Acute disseminated encephalomyelitis Measles virus" exact="Multiple" post="sclerosis Theilerâ€™s virus Multiple sclerosis Varicella-Zoster virus Multiple sclerosis"/>
 <result pre="Influenza Acute disseminated encephalomyelitis Measles virus Multiple sclerosis Theilerâ€™s virus" exact="Multiple" post="sclerosis Varicella-Zoster virus Multiple sclerosis West Nile virus Myasthenia"/>
 <result pre="Measles virus Multiple sclerosis Theilerâ€™s virus Multiple sclerosis Varicella-Zoster virus" exact="Multiple" post="sclerosis West Nile virus Myasthenia gravis Zika virus Guillain-BarrÃ©"/>
 <result pre="virus Multiple sclerosis Varicella-Zoster virus Multiple sclerosis West Nile virus" exact="Myasthenia gravis" post="Zika virus Guillain-BarrÃ© syndrome Chikungunya virus Symmetric polyarthritis Cytomegalovirus"/>
 <result pre="Multiple sclerosis West Nile virus Myasthenia gravis Zika virus Guillain-BarrÃ©" exact="syndrome" post="Chikungunya virus Symmetric polyarthritis Cytomegalovirus Rheumatoid arthritis, SLE Epstein-Barr"/>
 <result pre="gravis Zika virus Guillain-BarrÃ© syndrome Chikungunya virus Symmetric polyarthritis Cytomegalovirus" exact="Rheumatoid arthritis," post="SLE Epstein-Barr virus Rheumatoid arthritis Hepatitis C virus SLE,"/>
 <result pre="Chikungunya virus Symmetric polyarthritis Cytomegalovirus Rheumatoid arthritis, SLE Epstein-Barr virus" exact="Rheumatoid arthritis" post="Hepatitis C virus SLE, porphyria cutanea tarda Bystander effect"/>
 <result pre="virus Symmetric polyarthritis Cytomegalovirus Rheumatoid arthritis, SLE Epstein-Barr virus Rheumatoid" exact="arthritis" post="Hepatitis C virus SLE, porphyria cutanea tarda Bystander effect"/>
 <result pre="Symmetric polyarthritis Cytomegalovirus Rheumatoid arthritis, SLE Epstein-Barr virus Rheumatoid arthritis" exact="Hepatitis" post="C virus SLE, porphyria cutanea tarda Bystander effect Hepatitis"/>
 <result pre="arthritis, SLE Epstein-Barr virus Rheumatoid arthritis Hepatitis C virus SLE," exact="porphyria" post="cutanea tarda Bystander effect Hepatitis C virus Vasculitis, cryoglobulinemia,"/>
 <result pre="arthritis Hepatitis C virus SLE, porphyria cutanea tarda Bystander effect" exact="Hepatitis" post="C virus Vasculitis, cryoglobulinemia, Sjogren Syndrome, thrombocytopenia Enteroviruses Type"/>
 <result pre="tarda Bystander effect Hepatitis C virus Vasculitis, cryoglobulinemia, Sjogren Syndrome," exact="thrombocytopenia" post="Enteroviruses Type 1 diabetes mellitus Herpes simplex virus Stromal"/>
 <result pre="effect Hepatitis C virus Vasculitis, cryoglobulinemia, Sjogren Syndrome, thrombocytopenia Enteroviruses" exact="Type 1" post="diabetes mellitus Herpes simplex virus Stromal keratitis Human Herpesvirus"/>
 <result pre="C virus Vasculitis, cryoglobulinemia, Sjogren Syndrome, thrombocytopenia Enteroviruses Type 1" exact="diabetes mellitus" post="Herpes simplex virus Stromal keratitis Human Herpesvirus 6A Thyroiditis"/>
 <result pre="thrombocytopenia Enteroviruses Type 1 diabetes mellitus Herpes simplex virus Stromal" exact="keratitis" post="Human Herpesvirus 6A Thyroiditis Human immunodeficiency virus Autoantibodies in"/>
 <result pre="Herpes simplex virus Stromal keratitis Human Herpesvirus 6A Thyroiditis Human" exact="immunodeficiency" post="virus Autoantibodies in AIDS Influenza Acute disseminated encephalomyelitis Persistent"/>
 <result pre="Herpesvirus 6A Thyroiditis Human immunodeficiency virus Autoantibodies in AIDS Influenza" exact="Acute" post="disseminated encephalomyelitis Persistent infection and polyclonal activation Epstein-Barr virus"/>
 <result pre="Thyroiditis Human immunodeficiency virus Autoantibodies in AIDS Influenza Acute disseminated" exact="encephalomyelitis" post="Persistent infection and polyclonal activation Epstein-Barr virus Lymphoproliferation Hepatitis"/>
 <result pre="immunodeficiency virus Autoantibodies in AIDS Influenza Acute disseminated encephalomyelitis Persistent" exact="infection" post="and polyclonal activation Epstein-Barr virus Lymphoproliferation Hepatitis C virus"/>
 <result pre="disseminated encephalomyelitis Persistent infection and polyclonal activation Epstein-Barr virus Lymphoproliferation" exact="Hepatitis" post="C virus Mixed cryoglobulinemia AIDS acquired immunodeficiency syndrome, SLE"/>
 <result pre="infection and polyclonal activation Epstein-Barr virus Lymphoproliferation Hepatitis C virus" exact="Mixed" post="cryoglobulinemia AIDS acquired immunodeficiency syndrome, SLE systemic lupus erythematosus"/>
 <result pre="and polyclonal activation Epstein-Barr virus Lymphoproliferation Hepatitis C virus Mixed" exact="cryoglobulinemia" post="AIDS acquired immunodeficiency syndrome, SLE systemic lupus erythematosus Molecular"/>
 <result pre="activation Epstein-Barr virus Lymphoproliferation Hepatitis C virus Mixed cryoglobulinemia AIDS" exact="acquired immunodeficiency syndrome," post="SLE systemic lupus erythematosus Molecular mimicry Molecular mimicry, as"/>
 <result pre="Epstein-Barr virus Lymphoproliferation Hepatitis C virus Mixed cryoglobulinemia AIDS acquired" exact="immunodeficiency" post="syndrome, SLE systemic lupus erythematosus Molecular mimicry Molecular mimicry,"/>
 <result pre="Hepatitis C virus Mixed cryoglobulinemia AIDS acquired immunodeficiency syndrome, SLE" exact="systemic" post="lupus erythematosus Molecular mimicry Molecular mimicry, as a result"/>
 <result pre="C virus Mixed cryoglobulinemia AIDS acquired immunodeficiency syndrome, SLE systemic" exact="lupus erythematosus" post="Molecular mimicry Molecular mimicry, as a result of the"/>
 <result pre="mechanism plays a vital role in the pathogenesis of prototype" exact="systemic" post="rheumatological diseases such as rheumatoid arthritis (RA), systemic lupus"/>
 <result pre="in the pathogenesis of prototype systemic rheumatological diseases such as" exact="rheumatoid arthritis" post="(RA), systemic lupus erythematosus (SLE), systemic sclerosis, and Sjogren"/>
 <result pre="the pathogenesis of prototype systemic rheumatological diseases such as rheumatoid" exact="arthritis" post="(RA), systemic lupus erythematosus (SLE), systemic sclerosis, and Sjogren"/>
 <result pre="of prototype systemic rheumatological diseases such as rheumatoid arthritis (RA)," exact="systemic" post="lupus erythematosus (SLE), systemic sclerosis, and Sjogren syndrome [54]."/>
 <result pre="prototype systemic rheumatological diseases such as rheumatoid arthritis (RA), systemic" exact="lupus erythematosus" post="(SLE), systemic sclerosis, and Sjogren syndrome [54]. SARS-CoV-2 proteins"/>
 <result pre="diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)," exact="systemic" post="sclerosis, and Sjogren syndrome [54]. SARS-CoV-2 proteins displayed at"/>
 <result pre="rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and" exact="Sjogren syndrome" post="[54]. SARS-CoV-2 proteins displayed at least one match with"/>
 <result pre="arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and Sjogren" exact="syndrome" post="[54]. SARS-CoV-2 proteins displayed at least one match with"/>
 <result pre="human protein on a comparative peptidome analysis comprising of 37" exact="viral" post="proteins [55]. These similarities potentially can lead to loss"/>
 <result pre="2â€²-O-ribose methyltransferase, RNA-dependent RNA polymerase and 3â€²-to-5â€² exonuclease proteins from" exact="autoimmune" post="dermatomyositis patients matching with the SARS-CoV-2 peptides [56]. Fig."/>
 <result pre="methyltransferase, RNA-dependent RNA polymerase and 3â€²-to-5â€² exonuclease proteins from autoimmune" exact="dermatomyositis" post="patients matching with the SARS-CoV-2 peptides [56]. Fig. 1"/>
 <result pre="cells and proinflammation: The cytoplasmic pattern recognition receptors after identifying" exact="viral" post="RNA phosphorylates downstream IRF-3, IRF-7, and NFÎºB leading to"/>
 <result pre="IRF interferon regulatory transcription factor, ISRE interferon-stimulated response element, MDA-5" exact="melanoma" post="differentiation-associated protein-5, MVAS mitochondrialÂ antiviral-signaling protein, MYD88 myeloid differentiation"/>
 <result pre="melanoma differentiation-associated protein-5, MVAS mitochondrialÂ antiviral-signaling protein, MYD88 myeloid differentiation" exact="primary" post="response-88, RIG-1 retinoic acid-inducible gene-I, NF-ÎºB nuclear factor kappa-light-chain-enhancer"/>
 <result pre="factor kappa-light-chain-enhancer of activated B cells), TLR toll-like receptor, TNF" exact="tumor" post="necrosis factor In addition to the presence of cross-reactive"/>
 <result pre="activation of antigen-presenting cells (APCs) either by an adjuvant or" exact="infectious" post="stimulus is essential to increase the expression of co-receptors"/>
 <result pre="stimulus is essential to increase the expression of co-receptors [51]." exact="Viral" post="RNA of the SARS-CoV-2 activates dendritic cells through cytosolic"/>
 <result pre="[51]. Viral RNA of the SARS-CoV-2 activates dendritic cells through" exact="cytosolic" post="RIG like receptors and endosomal TLRs, as well as"/>
 <result pre="of initial asymptomatic to mild symptoms followed by severe autoinflammatory" exact="syndrome" post="in COVID-19 is proposed to be due to a"/>
 <result pre="be due to a similar autoreactive adaptive response with SARS-CoV-2" exact="infection" post="[3]. The role of genetic susceptibility should also be"/>
 <result pre="the common human coronaviruses [58]. The association of HLA-B*15 with" exact="primary" post="Sjogrenâ€™s syndrome [59] and Bechetâ€™s diseases [60] is well"/>
 <result pre="human coronaviruses [58]. The association of HLA-B*15 with primary Sjogrenâ€™s" exact="syndrome" post="[59] and Bechetâ€™s diseases [60] is well documented, and"/>
 <result pre="theory of epitope spreading [62, 63]. In SLE, before clinical" exact="disease" post="onset, autoantibodies are targeted against Ro, La, and phospholipid"/>
 <result pre="with positive autoantibodies. Bystander activation and damage Pre-clinical studies of" exact="diabetes" post="and experimental autoimmune encephalomyelitis suggest the role of bystander"/>
 <result pre="autoantibodies. Bystander activation and damage Pre-clinical studies of diabetes and" exact="experimental autoimmune encephalomyelitis" post="suggest the role of bystander activation as one of"/>
 <result pre="Bystander activation and damage Pre-clinical studies of diabetes and experimental" exact="autoimmune" post="encephalomyelitis suggest the role of bystander activation as one"/>
 <result pre="activation and damage Pre-clinical studies of diabetes and experimental autoimmune" exact="encephalomyelitis" post="suggest the role of bystander activation as one of"/>
 <result pre="generation of autoreactive cells (Fig.Â 2) [51]. The association of" exact="hepatitis C" post="virus and Sjogren syndrome serves a classical example among"/>
 <result pre="(Fig.Â 2) [51]. The association of hepatitis C virus and" exact="Sjogren syndrome" post="serves a classical example among RMDs explaining the bystander"/>
 <result pre="2) [51]. The association of hepatitis C virus and Sjogren" exact="syndrome" post="serves a classical example among RMDs explaining the bystander"/>
 <result pre="among RMDs explaining the bystander activation and damage theory [69]." exact="Hepatitis" post="C, primarily a hepatotropic virus, also exhibits sialotropism and"/>
 <result pre="exhibits sialotropism and lymphotropism leading to bystander activation of the" exact="salivary gland" post="epithelium and lymphocytes, respectively [70]. The activation of salivary"/>
 <result pre="gland epithelium and lymphocytes, respectively [70]. The activation of salivary" exact="epithelial" post="cells and resultant antiviral defense in the salivary gland"/>
 <result pre="of salivary epithelial cells and resultant antiviral defense in the" exact="salivary gland" post="result in bystander damage manifesting as sicca symptoms and"/>
 <result pre="documented in severe cases of SARS-CoV-2. The reduction is possibly" exact="secondary" post="to functional exhaustion and preferential accumulation of the primed"/>
 <result pre="preferential accumulation of the primed lymphocytes at the site of" exact="viral infection" post="[71]. These preferentially accumulated lymphocytes exhibit increased activity as"/>
 <result pre="accumulation of the primed lymphocytes at the site of viral" exact="infection" post="[71]. These preferentially accumulated lymphocytes exhibit increased activity as"/>
 <result pre="reactive oxygen species [72]. With SARS-CoV-2 infection, the multisystem inflammatory" exact="syndrome" post="appears after the peak of viral load. This suggests"/>
 <result pre="infection, the multisystem inflammatory syndrome appears after the peak of" exact="viral" post="load. This suggests a build-up of inflammatory cytokine and"/>
 <result pre="reported with SARS-CoV-2 infection. Autopsy reports of COVID-19 patients show" exact="diffuse" post="infiltration of lymphocytes in the lungs and focal infiltration"/>
 <result pre="patients show diffuse infiltration of lymphocytes in the lungs and" exact="focal" post="infiltration in the heart, kidney, liver, pancreas, and adrenal"/>
 <result pre="sequestered autoantigen presentation leading to the emergence of neoepitope and" exact="autoimmune" post="manifestations, as seen in SLE [75]. Persistent immune activation"/>
 <result pre="SLE [75]. Persistent immune activation The third theory of persistent" exact="viral infection" post="and oligo/polyclonal activation can be explained by the constant"/>
 <result pre="[75]. Persistent immune activation The third theory of persistent viral" exact="infection" post="and oligo/polyclonal activation can be explained by the constant"/>
 <result pre="oligo/polyclonal activation can be explained by the constant presence of" exact="viral" post="antigens driving immune-proliferation resulting from the ineffective clearance of"/>
 <result pre="autoreactive B cells cause lymphoproliferation and polyclonal activation culminating in" exact="chronic" post="autoimmunity [77]. As the possibility of the persistence of"/>
 <result pre="to an additional mechanism of autoimmunity. On a brighter side," exact="complete" post="clearance is reported in cases of other members of"/>
 <result pre="noted the formation of neutrophil extracellular traps (NETs) by demonstrating" exact="elevated serum" post="levels of cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone"/>
 <result pre="oxidant enzymes from neutrophilic granules. The principal role of this" exact="transient" post="phenomenon is to trap the microorganisms to resolve the"/>
 <result pre="resolve the infection. However, sustained netosis may beget inflammation and" exact="thrombosis" post="[80]. In the past decade, researchers have established the"/>
 <result pre="past decade, researchers have established the role of netosis in" exact="autoimmune disease" post="including but not limited to, SLE, RA, anti-neutrophil cytoplasmic"/>
 <result pre="decade, researchers have established the role of netosis in autoimmune" exact="disease" post="including but not limited to, SLE, RA, anti-neutrophil cytoplasmic"/>
 <result pre="the role of netosis in autoimmune disease including but not" exact="limited" post="to, SLE, RA, anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), antiphospholipid"/>
 <result pre="including but not limited to, SLE, RA, anti-neutrophil cytoplasmic antibody-associated" exact="vasculitis" post="(AAV), antiphospholipid antibody syndrome (APS), and an autoinflammatory syndrome,"/>
 <result pre="not limited to, SLE, RA, anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)," exact="antiphospholipid antibody syndrome" post="(APS), and an autoinflammatory syndrome, deficiency of adenosine deaminase-2"/>
 <result pre="to, SLE, RA, anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), antiphospholipid antibody" exact="syndrome" post="(APS), and an autoinflammatory syndrome, deficiency of adenosine deaminase-2"/>
 <result pre="vasculitis (AAV), antiphospholipid antibody syndrome (APS), and an autoinflammatory syndrome," exact="deficiency" post="of adenosine deaminase-2 (DADA-2) [81]. In COVID-19, a rise"/>
 <result pre="[81]. In COVID-19, a rise in neutrophil counts during early" exact="infection" post="is a poor prognostic factor. The migration of these"/>
 <result pre="factors play an important role in susceptibility and protection to" exact="autoimmune disease" post="[45]. A paradigm shift has taken place in the"/>
 <result pre="play an important role in susceptibility and protection to autoimmune" exact="disease" post="[45]. A paradigm shift has taken place in the"/>
 <result pre="The positive side is reflected by a reduction in airborne" exact="infectious disease" post="with a documented shortening of the influenza season in"/>
 <result pre="positive side is reflected by a reduction in airborne infectious" exact="disease" post="with a documented shortening of the influenza season in"/>
 <result pre="This may reduce the occurrence of subsequent effects of influenza" exact="infection" post="on RMDs. Diseases like acute rheumatic fever, where overcrowding"/>
 <result pre="the occurrence of subsequent effects of influenza infection on RMDs." exact="Diseases" post="like acute rheumatic fever, where overcrowding plays an essential"/>
 <result pre="of subsequent effects of influenza infection on RMDs. Diseases like" exact="acute" post="rheumatic fever, where overcrowding plays an essential role in"/>
 <result pre="subsequent effects of influenza infection on RMDs. Diseases like acute" exact="rheumatic" post="fever, where overcrowding plays an essential role in familial"/>
 <result pre="acute rheumatic fever, where overcrowding plays an essential role in" exact="familial" post="predisposition may also reduce with these hygienic measures [85]."/>
 <result pre="the negative spectrum of these hygienic measures, an increase in" exact="autoimmune disease" post="should be born in mind as proposed by the"/>
 <result pre="negative spectrum of these hygienic measures, an increase in autoimmune" exact="disease" post="should be born in mind as proposed by the"/>
 <result pre="in lifestyle especially in the developed world, the burden of" exact="infectious disease" post="reduced with a parallel increase in autoimmune diseases like"/>
 <result pre="lifestyle especially in the developed world, the burden of infectious" exact="disease" post="reduced with a parallel increase in autoimmune diseases like"/>
 <result pre="burden of infectious disease reduced with a parallel increase in" exact="autoimmune diseases" post="like type1 diabetes mellitus, inflammatory bowel disease, and multiple"/>
 <result pre="reduced with a parallel increase in autoimmune diseases like type1" exact="diabetes mellitus," post="inflammatory bowel disease, and multiple sclerosis [86]. One of"/>
 <result pre="a parallel increase in autoimmune diseases like type1 diabetes mellitus," exact="inflammatory bowel disease," post="and multiple sclerosis [86]. One of the key influencers"/>
 <result pre="parallel increase in autoimmune diseases like type1 diabetes mellitus, inflammatory" exact="bowel" post="disease, and multiple sclerosis [86]. One of the key"/>
 <result pre="autoimmune diseases like type1 diabetes mellitus, inflammatory bowel disease, and" exact="multiple sclerosis" post="[86]. One of the key influencers to hygiene hypothesis"/>
 <result pre="microbiome of an individual which plays a protective role against" exact="autoimmune diseases." post="The mechanisms conferring protections by microbiome include antigenic competition,"/>
 <result pre="Disturbance in this microbiome is evident in the pathogenesis of" exact="autoimmune" post="disorders including RA, SLE, and inflammatory bowel disease [88]."/>
 <result pre="in the pathogenesis of autoimmune disorders including RA, SLE, and" exact="inflammatory bowel disease" post="[88]. Over practice of distancing and antimicrobial sanitizers may"/>
 <result pre="the pathogenesis of autoimmune disorders including RA, SLE, and inflammatory" exact="bowel" post="disease [88]. Over practice of distancing and antimicrobial sanitizers"/>
 <result pre="pathogenesis of autoimmune disorders including RA, SLE, and inflammatory bowel" exact="disease" post="[88]. Over practice of distancing and antimicrobial sanitizers may"/>
 <result pre="triggering autoimmunity. Additionally, the psychological stress caused by isolation, the" exact="anxiety" post="of contracting the infection, and the economic burden along"/>
 <result pre="long-term socio-economic consequences can turn as a trigger of various" exact="autoimmune diseases" post="[89]. In summary, understanding the immune consequences of SARS-Cov-2"/>
 <result pre="along with the environmental changes may explain the basis of" exact="rheumatic" post="musculoskeletal manifestations. Preventive therapy against SARS-CoV-2 and the risk"/>
 <result pre="Currently, a multitude of vaccines for the prevention of SARS-CoV-2" exact="infection" post="is under investigation [90]. Except for the nucleocapsid, all"/>
 <result pre="with human proteins [55]. This homology between the human and" exact="viral" post="proteins is an established factor in vaccine-induced autoimmunity with"/>
 <result pre="the risk of pathogenic priming. Targeted immunosuppressive therapy for SARS-CoV-2" exact="infection" post="The clinical outcome of the patients relies on the"/>
 <result pre="possibly achieved with immunomodulatory therapies repurposed from drugs used in" exact="autoimmune diseases." post="The potential drug targets for COVID-19 has been reviewed"/>
 <result pre="Misra et al. [8]. In the early asymptomatic or mild" exact="symptomatic" post="stage, antiviral therapy is likely to have maximum efficacy,"/>
 <result pre="augmenting the innate antiviral response. In the next stage of" exact="pulmonary" post="and systemic hyper-inflammation, early initiation of immunosuppressant, including IVIg,"/>
 <result pre="innate antiviral response. In the next stage of pulmonary and" exact="systemic" post="hyper-inflammation, early initiation of immunosuppressant, including IVIg, corticosteroids, IL-6,"/>
 <result pre="they are significant drivers of proinflammation in the cytokine release" exact="syndrome" post="(CRS) of COVID-19. The IL-1 receptor antagonist, anakinra, has"/>
 <result pre="anakinra, has proven its beneficial effects in the MAS in" exact="rheumatic" post="diseases, as well as in chimeric antigen receptor T"/>
 <result pre="receptor T cell (CAR-T)-mediated severe CRS [96, 97]. Data from" exact="uncontrolled" post="or historically controlled case series are encouraging for anakinra"/>
 <result pre="of IL-6 in COVID-19 patients results from the secretion through" exact="viral" post="infected respiratory cells, as well as from the infiltrating"/>
 <result pre="in COVID-19 patients results from the secretion through viral infected" exact="respiratory" post="cells, as well as from the infiltrating lymphocytes and"/>
 <result pre="through viral infected respiratory cells, as well as from the" exact="infiltrating" post="lymphocytes and monocytes [99]. The anti-IL-6 treatment strategy has"/>
 <result pre="efficacy in a similar CRS-like phenomenon observed with MAS in" exact="rheumatic" post="diseases and has become an attractive target for COVID-19"/>
 <result pre="of tocilizumab (a monoclonal antibody against the IL-6 receptor) is" exact="limited" post="to observational studies [101]. The results of ongoing randomized"/>
 <result pre="downstream effects of IL-6 and its receptor are mediated via" exact="cytosolic" post="Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling,"/>
 <result pre="for COVID-19: Macrophages play a significant role in cytokine release" exact="syndrome" post="associated with SARS-CoV-2 infection. The cells get activated directly"/>
 <result pre="at present for the treatment of COVID-19. (1) TLR7 mediated" exact="viral" post="signaling at the endosomal levelâ€&quot;&amp;gt;â€‰chloroquine and hydroxychloroquine. (2) TLR4-TRIF"/>
 <result pre="transcription factor, ISRE interferon-stimulated response element, JAK Janus kinase, MDA-5" exact="melanoma" post="differentiation-associated protein-5, MVAS mitochondrialÂ antiviral-signaling protein, MYD88 myeloid differentiation"/>
 <result pre="melanoma differentiation-associated protein-5, MVAS mitochondrialÂ antiviral-signaling protein, MYD88 myeloid differentiation" exact="primary" post="response-88, RIG-1 retinoic acid-inducible gene-I, NF-ÎºB nuclear factor kappa-light-chain-enhancer"/>
 <result pre="signal transducer and activator of transcription, TLR toll-like receptor, TNF" exact="tumor" post="necrosis factor Conclusion In this review, we primarily aimed"/>
 <result pre="novel RMDs, RMD mimics, and other manifestations, including cytokine storm," exact="Kawasaki disease," post="and coagulopathy. The immune consequences of SARS-CoV-2-host interaction along"/>
 <result pre="interaction along with the environmental changes, explain the basis of" exact="rheumatic" post="musculoskeletal manifestations of COVID-19. There is a need for"/>
 <result pre="a need for preparedness for a possible surge in diverse" exact="autoimmune diseases" post="following the pandemic. The rheumatology community is already joining"/>
 <result pre="this preparedness may help in the effective management of the" exact="rheumatic" post="manifestations of SARS-CoV-2 infection in the post-COVID-19 era. Publisher's"/>
 <result pre="in the effective management of the rheumatic manifestations of SARS-CoV-2" exact="infection" post="in the post-COVID-19 era. Publisher's Note Springer Nature remains"/>
 <result pre="they have no conflict of interest. References References 1.WHO Coronavirus" exact="Disease" post="(COVID-19) Dashboard. https://covid19.who.int/?gclid=Cj0KCQjwwr32BRD4ARIsAAJNf_0jdmZQ1hkz7onImyjahwc-N0H4WTwXnVU7bgQObfk_Vct9yucybbkaAk0oEALw_wcB. Accessed 28 May 2020 2.El-AzizTMAStockandJDRecent progress"/>
 <result pre="and interventionNat Rev Immunol202010.1038/s41577-020-0311-832346093 4.VerdoniLMazzaAGervasoniAet al.An outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
 <result pre="SARS-CoV-2 epidemic: an observational cohort studyLancet Lond Engl202010.1016/S0140-6736(20)31103-X 5.ToscanoGPalmeriniFRavagliaSet al.Guillain-BarrÃ©" exact="Syndrome" post="associated with SARS-CoV-2N Engl J Med202010.1056/NEJMc200919132302082 6.AlbertiPBerettaSPiattiMet al.Guillain-BarrÃ© syndrome"/>
 <result pre="al.Guillain-BarrÃ© Syndrome associated with SARS-CoV-2N Engl J Med202010.1056/NEJMc200919132302082 6.AlbertiPBerettaSPiattiMet al.Guillain-BarrÃ©" exact="syndrome" post="related to COVID-19 infectionNeurol Neuroimmunol Neuroinflammation202074e74110.1212/NXI.0000000000000741 7.collab: The Lancet"/>
 <result pre="fosters collaboration in rheumatology communityLancet Rheumatol202010.1016/S2665-9913(20)30082-532501451 8.MisraDPAgarwalVGasparyanAYZimbaORheumatologistsâ€™ perspective on coronavirus" exact="disease" post="19 (COVID-19) and potential therapeutic targetsClin Rheumatol202010.1007/s10067-020-05073-932277367 9.Ramos-CasalsMBrahmerJRCallahanMKet al.Immune-related"/>
 <result pre="inhibitorsNat Rev Dis Primer20206112110.1038/s41572-020-0160-6 10.KostineMCappelliLCCalabreseCet al.Addressing immune-related adverse events of" exact="cancer" post="immunotherapy: how prepared are rheumatologists?Ann Rheum Dis201978686086210.1136/annrheumdis-2018-21474830659050 11.BatlleDWysockiJSatchell K"/>
 <result pre="(2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus" exact="infection" post="therapy?Clin Sci Lond Engl1979134554354510.1042/CS20200163 12.HammingITimensWBulthuisMLelyANavisGvan GoorHTissue distribution of ACE2"/>
 <result pre="pathogenesisJ Pathol2004203263163710.1002/path.157015141377 13.WuZMcGooganJMCharacteristics of and Important Lessons From the Coronavirus" exact="Disease" post="2019 (COVID-19) Outbreak in China: summary of a Report"/>
 <result pre="Report of 72 314 Cases From the Chinese Center for" exact="Disease" post="Control and PreventionJAMA2020323131239124210.1001/jama.2020.2648 14.GiacomelliAPezzatiLContiFet al.Self-reported olfactory and taste disorders"/>
 <result pre="14.GiacomelliAPezzatiLContiFet al.Self-reported olfactory and taste disorders in patients with severe" exact="acute" post="respiratory coronavirus 2 infection: a cross-sectional studyClin Infect Dis202010.1093/cid/ciaa33032407467"/>
 <result pre="al.Self-reported olfactory and taste disorders in patients with severe acute" exact="respiratory" post="coronavirus 2 infection: a cross-sectional studyClin Infect Dis202010.1093/cid/ciaa33032407467 15.LechienJRChiesa-EstombaCMHansSBarillariMRJouffeLSaussezSLoss"/>
 <result pre="al.Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected" exact="disease" post="2019 (COVID-19) with gastrointestinal symptomsGut20206961002100910.1136/gutjnl-2020-32092632213556 17.GoyalPChoiJJPinheiroLCet al.Clinical characteristics of"/>
 <result pre="in New York CityN Engl J Med2020382242372237410.1056/NEJMc201041932302078 18.WuPDuanFLuoCet al.Characteristics of" exact="ocular" post="findings of patients with coronavirus disease 2019 (COVID-19) in"/>
 <result pre="Med2020382242372237410.1056/NEJMc201041932302078 18.WuPDuanFLuoCet al.Characteristics of ocular findings of patients with coronavirus" exact="disease" post="2019 (COVID-19) in Hubei ProvinceChina JAMA Ophthalmol2020138557557810.1001/jamaophthalmol.2020.1291 19.CDC Coronavirus"/>
 <result pre="disease 2019 (COVID-19) in Hubei ProvinceChina JAMA Ophthalmol2020138557557810.1001/jamaophthalmol.2020.1291 19.CDC Coronavirus" exact="Disease" post="2019 (COVID-19) Centers for Disease Control and Prevention (2020)."/>
 <result pre="ProvinceChina JAMA Ophthalmol2020138557557810.1001/jamaophthalmol.2020.1291 19.CDC Coronavirus Disease 2019 (COVID-19) Centers for" exact="Disease" post="Control and Prevention (2020). https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html 20.GianfrancescoMAHyrichKLGossecLet al.Rheumatic disease and"/>
 <result pre="Centers for Disease Control and Prevention (2020). https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html 20.GianfrancescoMAHyrichKLGossecLet al.Rheumatic" exact="disease" post="and COVID-19: initial data from the COVID-19 Global Rheumatology"/>
 <result pre="CatalÃ A, HernÃ¡ndez GC, et al (2020) Classification of the" exact="cutaneous" post="manifestations of COVID-19: a rapid prospective nationwide consensus study"/>
 <result pre="Spain with 375 cases. Br J Dermatol. 10.1111/bjd.19163 24.OxleyTJMoccoJMajidiSet al.Large-vessel" exact="stroke" post="as a presenting feature of Covid-19 in the youngN"/>
 <result pre="J Med202038220e6010.1056/NEJMc200978732343504 25.InciardiRMLupiLZacconeGet al.Cardiac involvement in a patient with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.109632219357 26.KimI-CKimJYKimHAHanSCOVID-19-related myocarditis in a 21-year-old female"/>
 <result pre="in a patient with coronavirus disease 2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.109632219357 26.KimI-CKimJYKimHAHanSCOVID-19-related" exact="myocarditis" post="in a 21-year-old female patientEur Heart J202041191859185910.1093/eurheartj/ehaa28832282027 27.MehtaPMcAuleyDFBrownMSanchezETattersallRSMansonJJCOVID-19: consider"/>
 <result pre="coronavirus disease 2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.109632219357 26.KimI-CKimJYKimHAHanSCOVID-19-related myocarditis in a 21-year-old" exact="female" post="patientEur Heart J202041191859185910.1093/eurheartj/ehaa28832282027 27.MehtaPMcAuleyDFBrownMSanchezETattersallRSMansonJJCOVID-19: consider cytokine storm syndromes and"/>
 <result pre="2019 (COVID-19)JAMA Cardiol202010.1001/jamacardio.2020.109632219357 26.KimI-CKimJYKimHAHanSCOVID-19-related myocarditis in a 21-year-old female patientEur" exact="Heart" post="J202041191859185910.1093/eurheartj/ehaa28832282027 27.MehtaPMcAuleyDFBrownMSanchezETattersallRSMansonJJCOVID-19: consider cytokine storm syndromes and immunosuppressionLancet2020395102291033103410.1016/S0140-6736(20)30628-032192578 28.GazzarusoCCarlo"/>
 <result pre="and immunosuppressionLancet2020395102291033103410.1016/S0140-6736(20)30628-032192578 28.GazzarusoCCarlo StellaNMarianiGet al.High prevalence of antinuclear antibodies and" exact="lupus" post="anticoagulant in patients hospitalized for SARS-CoV2 pneumoniaClin Rheumatol202010.1007/s10067-020-05180-732548723 29.HarzallahIDebliquisADrÃ©nouBLupus"/>
 <result pre="Med202038217e3810.1056/NEJMc200757532268022 31.ZhouFYuTDuRet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="profile of ribavirin and monitoring of its plasma concentration in" exact="Chronic" post="Hepatitis C InfectionJ Clin Exp Hepatol201221425410.1016/S0973-6883(12)60090-525755405 37.PsarrasAEmeryPVitalEMType I interferonâ€&quot;mediated"/>
 <result pre="of ribavirin and monitoring of its plasma concentration in Chronic" exact="Hepatitis" post="C InfectionJ Clin Exp Hepatol201221425410.1016/S0973-6883(12)60090-525755405 37.PsarrasAEmeryPVitalEMType I interferonâ€&quot;mediated autoimmune"/>
 <result pre="Chronic Hepatitis C InfectionJ Clin Exp Hepatol201221425410.1016/S0973-6883(12)60090-525755405 37.PsarrasAEmeryPVitalEMType I interferonâ€&quot;mediated" exact="autoimmune" post="diseases: pathogenesis, diagnosis and targeted therapyRheumatology201756101662167510.1093/rheumatology/kew43128122959 38.TangNLiDWangXSunZAbnormal coagulation parameters"/>
 <result pre="with novel coronavirus pneumoniaJ Thromb Haemost202018484484710.1111/jth.1476832073213 39.WichmannDSperhakeJ-PLÃ¼tgehetmannMet al.Autopsy findings and" exact="venous thromboembolism" post="in patients With COVID-19Ann Intern Med202010.7326/M20-200332374815 40.LeviMThachilJIbaTLevyJHCoagulation abnormalities and"/>
 <result pre="thromboembolism in patients With COVID-19Ann Intern Med202010.7326/M20-200332374815 40.LeviMThachilJIbaTLevyJHCoagulation abnormalities and" exact="thrombosis" post="in patients with COVID-19Lancet Haematol202010.1016/S2352-3026(20)30145-932407672 41.ThachilJSrivastavaASARS-2 coronavirus-associated hemostatic lung"/>
 <result pre="Haematol202010.1016/S2352-3026(20)30145-932407672 41.ThachilJSrivastavaASARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it" exact="pulmonary thrombosis" post="or pulmonary embolism?Semin Thromb Hemost202010.1055/s-0040-171215532512589 42.StockschlaederMSchneppenheimRBuddeUUpdate on von Willebrand"/>
 <result pre="41.ThachilJSrivastavaASARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary" exact="thrombosis" post="or pulmonary embolism?Semin Thromb Hemost202010.1055/s-0040-171215532512589 42.StockschlaederMSchneppenheimRBuddeUUpdate on von Willebrand"/>
 <result pre="hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or" exact="pulmonary" post="embolism?Semin Thromb Hemost202010.1055/s-0040-171215532512589 42.StockschlaederMSchneppenheimRBuddeUUpdate on von Willebrand factor multimers:"/>
 <result pre="Fibrinolysis Int J Haemost Thromb201425320621610.1097/MBC.0000000000000065 43.ZuoYZuoMYalavarthiSet al.Neutrophil extracellular traps and" exact="thrombosis" post="in COVID-19MedRxiv202010.1101/2020.04.30.2008673632587992 44.TangNBaiHChenXGongJLiDSunZAnticoagulant treatment is associated with decreased mortality"/>
 <result pre="44.TangNBaiHChenXGongJLiDSunZAnticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ Thromb Haemost20201851094109910.1111/jth.1481732220112 45.ShoenfeldYIsenbergDAThe mosaic of"/>
 <result pre="mosaic of autoimmunityImmunol Today198910412312610.1016/0167-5699(89)90245-42665774 46.ArleevskayaMIManukyanGInoueRAminovREditorial: microbial and environmental factors in" exact="autoimmune" post="and inflammatory diseasesFront Immunol201710.3389/fimmu.2017.0024329259607 47.ToplakNAvÄ�inTInfluenza and autoimmunityAnn N Y"/>
 <result pre="Mol Neurosci201810.3389/fnmol.2018.0011629695953 49.TanayAChikungunya virus and autoimmunityCurr Opin Rheumatol201729438939310.1097/BOR.000000000000039628376065 50.Fausther-BovendoHQiuXMcCorristerSet al.Ebola" exact="virus infection" post="induces autoimmunity against dsDNA and HSP60Sci Rep201774214710.1038/srep4214728181533 51.FujinamiRSvon HerrathMGChristenUWhittonJLMolecular"/>
 <result pre="Neurosci201810.3389/fnmol.2018.0011629695953 49.TanayAChikungunya virus and autoimmunityCurr Opin Rheumatol201729438939310.1097/BOR.000000000000039628376065 50.Fausther-BovendoHQiuXMcCorristerSet al.Ebola virus" exact="infection" post="induces autoimmunity against dsDNA and HSP60Sci Rep201774214710.1038/srep4214728181533 51.FujinamiRSvon HerrathMGChristenUWhittonJLMolecular"/>
 <result pre="dsDNA and HSP60Sci Rep201774214710.1038/srep4214728181533 51.FujinamiRSvon HerrathMGChristenUWhittonJLMolecular mimicry, bystander activation, or" exact="viral" post="persistence: infections and autoimmune diseaseClin Microbiol Rev2006191809410.1128/CMR.19.1.80-94.200616418524 52.SmattiMKCyprianFSNasrallahGKAl ThaniAAAlmishalROYassineHMViruses"/>
 <result pre="HSP60Sci Rep201774214710.1038/srep4214728181533 51.FujinamiRSvon HerrathMGChristenUWhittonJLMolecular mimicry, bystander activation, or viral persistence:" exact="infections" post="and autoimmune diseaseClin Microbiol Rev2006191809410.1128/CMR.19.1.80-94.200616418524 52.SmattiMKCyprianFSNasrallahGKAl ThaniAAAlmishalROYassineHMViruses and autoimmunity:"/>
 <result pre="51.FujinamiRSvon HerrathMGChristenUWhittonJLMolecular mimicry, bystander activation, or viral persistence: infections and" exact="autoimmune" post="diseaseClin Microbiol Rev2006191809410.1128/CMR.19.1.80-94.200616418524 52.SmattiMKCyprianFSNasrallahGKAl ThaniAAAlmishalROYassineHMViruses and autoimmunity: a review"/>
 <result pre="mechanismsViruses201911876210.3390/v11080762 53.KimBKaisthaSDRouseBTViruses and autoimmunityAutoimmunity2006391717710.1080/0891693050048470816455584 54.CusickMFLibbeyJEFujinamiRSMolecular mimicry as a mechanism of" exact="autoimmune" post="diseaseClin Rev Allergy Immunol201242110211110.1007/s12016-011-8294-722095454 55.Lyons-WeilerJPathogenic priming likely contributes to"/>
 <result pre="epitopes with high sequence identity to SARS-CoV-2 in patients with" exact="autoimmune" post="dermatomyositisAnn Rheum Dis202010.1136/annrheumdis-2020-21752232444414 57.ToturaALBaricRSSARS coronavirus pathogenesis: host innate immune"/>
 <result pre="Rheum Dis202010.1136/annrheumdis-2020-21752232444414 57.ToturaALBaricRSSARS coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferonCurr Opin Virol20122326427510.1016/j.coviro.2012.04.00422572391 58.NguyenADavidJKMadenSKet al.Human leukocyte antigen"/>
 <result pre="map for SARS-CoV-2J Virol202010.1128/JVI.00510-2032321819 59.CharfiAMahfoudhNKamounAet al.Association of HLA Alleles with" exact="Primary" post="SjÃ¶gren Syndrome in the South Tunisian PopulationMed Princ Pract2020291323810.1159/00050189631272097"/>
 <result pre="SARS-CoV-2J Virol202010.1128/JVI.00510-2032321819 59.CharfiAMahfoudhNKamounAet al.Association of HLA Alleles with Primary SjÃ¶gren" exact="Syndrome" post="in the South Tunisian PopulationMed Princ Pract2020291323810.1159/00050189631272097 60.ChoukriFChakibAHimmichHHÃ¼eSCaillat-ZucmanSHLA-Bâˆ—51 and"/>
 <result pre="Princ Pract2020291323810.1159/00050189631272097 60.ChoukriFChakibAHimmichHHÃ¼eSCaillat-ZucmanSHLA-Bâˆ—51 and Bâˆ—15 alleles confer predisposition to BehÃ§etâ€™s" exact="disease" post="in Moroccan patientsHum Immunol200162218018510.1016/S0198-8859(00)00249-411182229 61.LehmannPVTargoniOSForsthuberTGShifting T-cell activation thresholds in"/>
 <result pre="Sci20039871919810.1111/j.1749-6632.2003.tb06036.x12727627 64.ArbuckleMRMcClainMTRubertoneMVet al.Development of autoantibodies before the clinical onset of" exact="systemic" post="lupus erythematosusN Engl J Med2003349161526153310.1056/NEJMoa02193314561795 65.HorwitzMSBradleyLMHarbertsonJKrahlTLeeJSarvennickNDiabetes induced by Coxsackie"/>
 <result pre="64.ArbuckleMRMcClainMTRubertoneMVet al.Development of autoantibodies before the clinical onset of systemic" exact="lupus" post="erythematosusN Engl J Med2003349161526153310.1056/NEJMoa02193314561795 65.HorwitzMSBradleyLMHarbertsonJKrahlTLeeJSarvennickNDiabetes induced by Coxsackie virus:"/>
 <result pre="and TNF-alpha pathways as specific and bystander killing mechanisms of" exact="hepatitis C" post="virus-specific human CTLJ Immunol199715811528352919164947 68.WucherpfennigKWStromingerJLMolecular mimicry in T cell-mediated"/>
 <result pre="virus-specific human CTLJ Immunol199715811528352919164947 68.WucherpfennigKWStromingerJLMolecular mimicry in T cell-mediated autoimmunity:" exact="viral" post="peptides activate human T cell clones specific for myelin"/>
 <result pre="cell clones specific for myelin basic proteinCell199580569570510.1016/0092-8674(95)90348-87534214 69.Ramos-CasalsMLoustaud-RattiVDe VitaSet al.SjÃ¶gren" exact="syndrome" post="associated with hepatitis C virus: a multicenter analysis of"/>
 <result pre="for myelin basic proteinCell199580569570510.1016/0092-8674(95)90348-87534214 69.Ramos-CasalsMLoustaud-RattiVDe VitaSet al.SjÃ¶gren syndrome associated with" exact="hepatitis C" post="virus: a multicenter analysis of 137 casesMedicine (Baltimore)2005842818910.1097/01.md.0000157397.30055.c915758837 70.Ramos-CasalsMGarcÃ­a-CarrascoMCerveraRFontJSjÃ¶grenâ€™s"/>
 <result pre="C virus: a multicenter analysis of 137 casesMedicine (Baltimore)2005842818910.1097/01.md.0000157397.30055.c915758837 70.Ramos-CasalsMGarcÃ­a-CarrascoMCerveraRFontJSjÃ¶grenâ€™s" exact="syndrome" post="and hepatitis C virusClin Rheumatol19991829310010.1007/s10067005006410357112 71.ZhengMGaoYWangGet al.Functional exhaustion of"/>
 <result pre="a multicenter analysis of 137 casesMedicine (Baltimore)2005842818910.1097/01.md.0000157397.30055.c915758837 70.Ramos-CasalsMGarcÃ­a-CarrascoMCerveraRFontJSjÃ¶grenâ€™s syndrome and" exact="hepatitis C" post="virusClin Rheumatol19991829310010.1007/s10067005006410357112 71.ZhengMGaoYWangGet al.Functional exhaustion of antiviral lymphocytes in"/>
 <result pre="in WuhanChina The Lancet20203951022349750610.1016/S0140-6736(20)30183-5 73.KimJYKoJHKimYet al.Viral load kinetics of SARS-CoV-2" exact="infection" post="in first two patients in KoreaJ Korean Med Sci2020357e8610.3346/jkms.2020.35.e8632080991"/>
 <result pre="Med Sci2020357e8610.3346/jkms.2020.35.e8632080991 74.EhrenfeldMTincaniAAndreoliLet al.Covid-19 and autoimmunityAutoimmun Rev202010.1016/j.autrev.2020.10259732535093 75.PodolskaMJBiermannMHMauerÃ¶derCHahnJHerrmannMInflammatory etiopathogenesis of" exact="systemic" post="lupus erythematosus: an updateJ Inflamm Res2015816117110.2147/JIR.S7032526316795 76.MatteucciDPagliantiMGiangregorioAMCapobianchiMRDianzaniFBendinelliMGroup B coxsackieviruses"/>
 <result pre="Sci2020357e8610.3346/jkms.2020.35.e8632080991 74.EhrenfeldMTincaniAAndreoliLet al.Covid-19 and autoimmunityAutoimmun Rev202010.1016/j.autrev.2020.10259732535093 75.PodolskaMJBiermannMHMauerÃ¶derCHahnJHerrmannMInflammatory etiopathogenesis of systemic" exact="lupus" post="erythematosus: an updateJ Inflamm Res2015816117110.2147/JIR.S7032526316795 76.MatteucciDPagliantiMGiangregorioAMCapobianchiMRDianzaniFBendinelliMGroup B coxsackieviruses readily"/>
 <result pre="an updateJ Inflamm Res2015816117110.2147/JIR.S7032526316795 76.MatteucciDPagliantiMGiangregorioAMCapobianchiMRDianzaniFBendinelliMGroup B coxsackieviruses readily establish persistent" exact="infections" post="in human lymphoid cell linesJ Virol198556265165410.1128/JVI.56.2.651-654.19852997486 77.NanboAInoueKAdachi-TakasawaKTakadaKEpstein-Barr virus RNA"/>
 <result pre="immunity and diseaseNat Rev Immunol201818213414710.1038/nri.2017.10528990587 81.WigerbladGKaplanMJNETs spread ever wider in" exact="rheumatic" post="diseasesNat Rev Rheumatol2020162737410.1038/s41584-019-0352-131853047 82.WangDHuBHuCet al.Clinical characteristics of 138 hospitalized"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in WuhanChina JAMA2020323111061106910.1001/jama.2020.1585 83.PapayannopoulosVMetzlerKDHakkimAZychlinskyANeutrophil elastase and myeloperoxidase regulate the"/>
 <result pre="regulate the formation of neutrophil extracellular trapsJ Cell Biol2010191367769110.1083/jcb.20100605220974816 84.ChanKHLeePChanCYLamKBHHoPMonitoring" exact="respiratory" post="infections in covid-19 epidemicsBMJ202010.1136/bmj.m162832366507 85.BakerMGGurneyJOliverJet al.Risk factors for acute"/>
 <result pre="the formation of neutrophil extracellular trapsJ Cell Biol2010191367769110.1083/jcb.20100605220974816 84.ChanKHLeePChanCYLamKBHHoPMonitoring respiratory" exact="infections" post="in covid-19 epidemicsBMJ202010.1136/bmj.m162832366507 85.BakerMGGurneyJOliverJet al.Risk factors for acute rheumatic"/>
 <result pre="84.ChanKHLeePChanCYLamKBHHoPMonitoring respiratory infections in covid-19 epidemicsBMJ202010.1136/bmj.m162832366507 85.BakerMGGurneyJOliverJet al.Risk factors for" exact="acute" post="rheumatic fever: literature review and protocol for a case-control"/>
 <result pre="respiratory infections in covid-19 epidemicsBMJ202010.1136/bmj.m162832366507 85.BakerMGGurneyJOliverJet al.Risk factors for acute" exact="rheumatic" post="fever: literature review and protocol for a case-control study"/>
 <result pre="should we go?Ann Rheum Dis202079672773310.1136/annrheumdis-2019-21663132332073 89.StojanovichLMarisavljevichDStress as a trigger of" exact="autoimmune" post="diseaseAutoimmun Rev20087320921310.1016/j.autrev.2007.11.00718190880 90.LeTTAndreadakisZKumarAet al.The COVID-19 vaccine development landscapeNat Rev"/>
 <result pre="receptor 2Sci Transl Med20157294294ra10510.1126/scitranslmed.aab235426136476 92.AgrawalASTaoXAlgaissiAet al.Immunization with inactivated Middle East" exact="Respiratory" post="Syndrome coronavirus vaccine leads to lung immunopathology on challenge"/>
 <result pre="2Sci Transl Med20157294294ra10510.1126/scitranslmed.aab235426136476 92.AgrawalASTaoXAlgaissiAet al.Immunization with inactivated Middle East Respiratory" exact="Syndrome" post="coronavirus vaccine leads to lung immunopathology on challenge with"/>
 <result pre="SARS-CoV bearing epidemic and zoonotic spike variantsPLoS Med2006312e52510.1371/journal.pmed.003052517194199 94.LiGFanYLaiYet al.Coronavirus" exact="infections" post="and immune responsesJ Med Virol202092442443210.1002/jmv.2568531981224 95.SiddiqiHKMehraMRCOVID-19 Illness in Native"/>
 <result pre="Illness in Native and Immunosuppressed States: a clinical-therapeutic staging proposalJ" exact="Heart" post="Lung Transpl202010.1016/j.healun.2020.03.012 96.SÃ¶nmezHEDemirSBilginerYÃ–zenSAnakinra treatment in macrophage activation syndrome: a"/>
 <result pre="treatment in macrophage activation syndrome: a single center experience and" exact="systemic" post="review of literatureClin Rheumatol201837123329333510.1007/s10067-018-4095-129663156 97.SantomassoBBachierCWestinJRezvaniKShpallEJThe other side of CAR"/>
 <result pre="systemic review of literatureClin Rheumatol201837123329333510.1007/s10067-018-4095-129663156 97.SantomassoBBachierCWestinJRezvaniKShpallEJThe other side of CAR" exact="T-Cell" post="therapy: cytokine release syndrome, neurologic toxicity, and financial burdenAm"/>
 <result pre="Rheumatol202010.1016/S2665-9913(20)30164-8 99.McGonagleDSharifKOâ€™ReganABridgewoodCThe role of cytokines including Interleukin-6 in COVID-19 induced" exact="pneumonia" post="and macrophage activation syndrome-like diseaseAutoimmun Rev202019610253710.1016/j.autrev.2020.10253732251717 100.WatanabeESugawaraHYamashitaTIshiiAOdaATeraiCSuccessful tocilizumab therapy"/>
 <result pre="activation syndrome-like diseaseAutoimmun Rev202019610253710.1016/j.autrev.2020.10253732251717 100.WatanabeESugawaraHYamashitaTIshiiAOdaATeraiCSuccessful tocilizumab therapy for macrophage activation" exact="syndrome" post="associated with adult-onset stillâ€™s disease: a case-based reviewCase Rep"/>
</results>
